TY - JOUR
T1 - Increases in arm volume predict lymphoedema and quality of life deficits after axillary surgery: a prospective cohort study
AU - Bundred, Nigel
AU - Foden, Phil
AU - Todd, Chris
AU - Morris, Julie
AU - Watterson, Donna
AU - Purushotham, Arnie
AU - Bramley, Maria
AU - Riches, Katie
AU - Hodgkiss, Tracey
AU - Evans, Abigail
AU - Skene, Anthony
AU - Keeley, Vaughan
N1 - Funding Information:
Funding information The trial was funded by the National Institute for Health Research (NIHR) Programme Grantfor Applied Research (RP-PG-0608-10168), held by Professor Bundred (Chief Investigator),Multi-frequency Bioimpedance devices (L-Dex U400) were loaned for the use of this studyby ImpediMed, Australia and Sigvaris provided sleeve for the study.
Publisher Copyright:
© 2020, The Author(s).
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/5/4
Y1 - 2020/5/4
N2 - Background
Lymphoedema develops after axillary clearance (ANC) in 25% of patients. This prospective, multi-centre study compared multi-frequency bioimpedance spectroscopy (BIS) with arm volume measurement to: (1) determine which test has better diagnostic accuracy, (2) identify factors predicting development of lymphoedema, and its effect on quality-of-life.
Methods
Participants (N = 1100) underwent measurements pre and post-ANC surgery for breast cancer. Relative arm volume increase (RAVI) of >10% diagnosed lymphoedema. Predictors of lymphoedema were determined using logistic regression. Optimal diagnostic method was assessed using diagnostic accuracy. Quality-of-life was assessed using the FACT B + 4 questionnaire.
Results
Lymphoedema was diagnosed in 22.8% women using RAVI > 10%, 45.6% using BIS criteria, while 24.5% underwent compression sleeve application by 24 months. BMI > 30 was an independent factor for both development (p = 0.005) and progression (p = 0.015) of lymphoedema. RAVI at 1 month, BMI > 30 and number of involved nodes contributed to a novel scoring model to predict lymphoedema by 36 months. Larger decreases in QoL scores post-surgery occurred in lymphoedema patients (p < 0.001). Progression to moderate lymphoedema occurred in 15% patients after sleeve application.
Conclusions
RAVI measurement was the best diagnostic tool for lymphoedema. BIS alone is not appropriate for lymphoedema screening or diagnosis. BMI > 30 predicted lymphoedema diagnosis and progression.
AB - Background
Lymphoedema develops after axillary clearance (ANC) in 25% of patients. This prospective, multi-centre study compared multi-frequency bioimpedance spectroscopy (BIS) with arm volume measurement to: (1) determine which test has better diagnostic accuracy, (2) identify factors predicting development of lymphoedema, and its effect on quality-of-life.
Methods
Participants (N = 1100) underwent measurements pre and post-ANC surgery for breast cancer. Relative arm volume increase (RAVI) of >10% diagnosed lymphoedema. Predictors of lymphoedema were determined using logistic regression. Optimal diagnostic method was assessed using diagnostic accuracy. Quality-of-life was assessed using the FACT B + 4 questionnaire.
Results
Lymphoedema was diagnosed in 22.8% women using RAVI > 10%, 45.6% using BIS criteria, while 24.5% underwent compression sleeve application by 24 months. BMI > 30 was an independent factor for both development (p = 0.005) and progression (p = 0.015) of lymphoedema. RAVI at 1 month, BMI > 30 and number of involved nodes contributed to a novel scoring model to predict lymphoedema by 36 months. Larger decreases in QoL scores post-surgery occurred in lymphoedema patients (p < 0.001). Progression to moderate lymphoedema occurred in 15% patients after sleeve application.
Conclusions
RAVI measurement was the best diagnostic tool for lymphoedema. BIS alone is not appropriate for lymphoedema screening or diagnosis. BMI > 30 predicted lymphoedema diagnosis and progression.
UR - http://www.scopus.com/inward/record.url?scp=85085140364&partnerID=8YFLogxK
U2 - 10.1038/s41416-020-0844-4
DO - 10.1038/s41416-020-0844-4
M3 - Article
C2 - 32362658
SN - 0007-0920
VL - 123
SP - 17
EP - 25
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 1
ER -